Sinonasal and respiratory outcomes of eosinophilic granulomatosis with polyangiitis patients receiving 100 mg mepolizumab in real-life clinical practice: 1-year follow up study

References

• Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, et al. 2012 revised ınternational chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11. doi:10.1002/art.37715.
   PubMed Web of Science ®Google Scholar
• Wu EY, Hernandez ML, Jennette JC, Falk RJ. Eosinophilic granulomatosis with polyangiitis: clinical pathology conference and review. J Allergy Clin Immunol Pract. 2018;6(5):1496–1504. doi:10.1016/j.jaip.2018.07.001.
   PubMed Web of Science ®Google Scholar
• Kalyoncu A, Karakaya G, Sahin A, Artvinli M. Experience of 10 years with Churg-Strauss syndrome: An accompaniment to or a transition from aspirin-induced asthma? Allergol Immunopathol (Madr). 2001;29(5):185–190. doi:10.1016/s0301-0546(01)79053-2.
   PubMedGoogle Scholar
• Seccia V, Baldini C, Latorre M, Gelardi M, Dallan I, Cristofani-Mencacci L, Sellari-Franceschini S, Bartoli ML, Bacci E, Paggiaro P, et al. Focus on the ınvolvement of the nose and paranasal sinuses in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): nasal cytology reveals ınfiltration of eosinophils as a very common feature. Int Arch Allergy Immunol. 2018;175(1-2):61–69. doi:10.1159/000484602.
   PubMed Web of Science ®Google Scholar
• Raffray L, Guillevin L. Updates for the treatment of EGPA. Presse Med. 2020;49(3):104036. doi:10.1016/j.lpm.2020.104036.
   PubMed Web of Science ®Google Scholar
• Khoury P, Grayson PC, Klion AD. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol. 2014;10(8):474–483. doi:10.1038/nrrheum.2014.98.
   PubMed Web of Science ®Google Scholar
• Bettiol A, Urban ML, Dagna L, Cottin V, Franceschini F, Del Giacco S, Schiavon F, Neumann T, Lopalco G, Novikov P, et al. European EGPA study group. mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study. Arthritis Rheumatol. 2022;74(2):295–306. doi:10.1002/art.41943.
   PubMed Web of Science ®Google Scholar
• Faverio P, Bonaiti G, Bini F, Vaghi A, Pesci A. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy. Ther Clin Risk Manag. 2018;14:2385–2396. doi:10.2147/TCRM.S159949.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, Merkel PA, Moosig F, Specks U, Cid MC, et al. EGPA mepolizumab study team. mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921–1932. doi:10.1056/NEJMoa1702079.
   PubMed Web of Science ®Google Scholar
• Caminati M, Crisafulli E, Lunardi C, Micheletto C, Festi G, Maule M, Giollo A, Orsolini G, Senna G. Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase. J Allergy Clin Immunol Pract. 2021;9(3):1386–1388. doi:10.1016/j.jaip.2020.09.025.
   PubMed Web of Science ®Google Scholar
• Detoraki A, Tremante E, Poto R, Morelli E, Quaremba G, Granata F, Romano A, Mormile I, Rossi FW, de Paulis A, et al. Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series. Respir Res. 2021;22(1):185. doi:10.1186/s12931-021-01775-z.
   PubMed Web of Science ®Google Scholar
• Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094–1100. doi:10.1002/art.1780330806.
   PubMed Web of Science ®Google Scholar
• Liu M, Liu J, Weitzel EK, Chen PG. The predictive utility of the 22-item sino-nasal outcome test (SNOT-22): a scoping review. Int Forum Allergy Rhinol. 2022;12(1):83–102. doi:10.1002/alr.22888.
   PubMedGoogle Scholar
• Toma S, Hopkins C. Stratification of SNOT-22 scores into mild, moderate or severe and relationship with other subjective instruments. Rhinology. 2016;54(2):129–133. doi:10.4193/Rhino15.072.
   PubMed Web of Science ®Google Scholar
• Feng AL, Wesely NC, Hoehle LP, Phillips KM, Yamasaki A, Campbell AP, Gregorio LL, Killeen TE, Caradonna DS, Meier JC, et al. A validated model for the 22-item Sino-Nasal Outcome Test subdomain structure in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2017;7(12):1140–1148. doi:10.1002/alr.22025.
   PubMed Web of Science ®Google Scholar
• Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59–65. doi:10.1016/j.jaci.2003.09.008.
   PubMed Web of Science ®Google Scholar
• Crimi C, Campisi R, Noto A, Genco S, Cacopardo G, Nolasco S, Crimi N. Comparability of asthma control test scores between self and physician-administered test. Respir Med. 2020;170(106015):106015. doi:10.1016/j.rmed.2020.106015.
   PubMedGoogle Scholar
• Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, Hallstrand TS, Kaminsky DA, McCarthy K, McCormack MC, et al. Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement. Am J Respir Crit Care Med. 2019;200(8):e70–e88. doi:10.1164/rccm.201908-1590ST.
   PubMed Web of Science ®Google Scholar
• Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cantón R, Torres A, Dimakou K, et al. European respiratory society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629. doi:10.1183/13993003.00629-2017.
   PubMed Web of Science ®Google Scholar
• Bhalla M, Turcios N, Aponte V, Jenkins M, Leitman BS, McCauley DI, Naidich DP. Cystic fibrosis: scoring system with thin-section CT. Radiology. 1991;179(3):783–788. doi:10.1148/radiology.179.3.2027992.
   PubMed Web of Science ®Google Scholar
• Lin X, Lin Y, Lai Z, Wei S, Qiu M, Li J, Liu Q, Chung KF, Zeng Q, Zhang Q, et al. Retrospective comparison of high-resolution computed tomography of eosinophilic granulomatosis with polyangiitis with severe asthma. Ann Transl Med. 2021;9(12):983–983. doi:10.21037/atm-21-2243.
   PubMed Web of Science ®Google Scholar
• Crimi C, Campisi R, Nolasco S, Cacopardo G, Intravaia R, Porto M, Impellizzeri P, Pelaia C, Crimi N. Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: a real-world retrospective pilot study. Respir Med. 2021;185(106491):106491. doi:10.1016/j.rmed.2021.106491.
   PubMedGoogle Scholar
• Crimi C, Campisi R, Cacopardo G, Intravaia R, Nolasco S, Porto M, Pelaia C, Crimi N. Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities. World Allergy Organ J. 2020;13(9):100462. doi:10.1016/j.waojou.2020.100462.
   PubMed Web of Science ®Google Scholar
• Crimi C, Campisi R, Nolasco S, Ferri S, Cacopardo G, Impellizzeri P, Pistorio MP, Fagone E, Pelaia C, Heffler E, et al. Type 2-high severe asthma with and without bronchiectasis: a prospective observational multicentre study. J Asthma Allergy. 2021;14:1441–1452. doi:10.2147/JAA.S332245.
   PubMed Web of Science ®Google Scholar
• Duran E, Bostan OC, Bilgin E, Kaya SB, Bolek EC, Ozer S, Damadoğlu E, Bilgen SA, Karakaya G, Karadag O, et al. The clinical features and treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in Turkey: one or two distinct diseases? Intern Emerg Med. 2022;17(3):743–751. doi:10.1007/s11739-021-02863-0.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X.
   PubMed Web of Science ®Google Scholar
• Roufosse F, Kahn J-E, Rothenberg ME, Wardlaw AJ, Klion AD, Kirby SY, Gilson MJ, Bentley JH, Bradford ES, Yancey SW, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;146(6):1397–1405. doi:10.1016/j.jaci.2020.08.037.
   PubMed Web of Science ®Google Scholar
• Vergles M, Matković Z, Lalić K, Trkanjec JT, Tudorić N. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient? J Asthma. 2021;58(12):1675–1679. doi:10.1080/02770903.2020.1827417.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Nencini F, Bormioli S, Vivarelli E, Dies L, Rossi O, Parronchi P, Maggi E, Matucci A. Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis. Allergy Asthma Immunol Res. 2020;12(5):885–893. doi:10.4168/aair.2020.12.5.885.
   PubMed Web of Science ®Google Scholar
• Nakamoto K, Saraya T, Ogawa Y, Ishii H, Takizawa H. Comparison of findings on thoracic computed tomography with the severity and duration of bronchial asthma in patients with eosinophilic granulomatosis with polyangiitis. Respir Med. 2018;139:101–105. doi:10.1016/j.rmed.2018.05.003.
   PubMed Web of Science ®Google Scholar
• Canzian A, Venhoff N, Urban ML, Sartorelli S, Ruppert A-M, Groh M, Girszyn N, Taillé C, Maurier F, Cottin V, et al. Use of biologics to treat relapsing and/or refractory eosinophilic granulomatosis with polyangiitis: data from a European collaborative study. Arthritis Rheumatol. 2021;73(3):498–503. doi:10.1002/art.41534.
   PubMed Web of Science ®Google Scholar